BIVI (BioVie) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIVI BioVie Inc BIVI
25 GF Score
Price $1.27
! 1 Warning Sign
View Full Analysis

What is BioVie Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.


BIVI vs BCLI, LNAI, TOVX: Short Interest Comparison

For the Biotechnology subindustry, BioVie's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVie Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVie's Short Interest distribution charts can be found below:

* The bar in red indicates where BioVie's Short Interest falls into.


BIVI
25GF Score
BioVie Inc BIVI
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVie Business Description

Address 680 W Nye Lane, Suite 204, Carson, NV, USA, 89703
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
25GF Score

Get the complete analysis for BIVI

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.27
Price